Patents by Inventor Eric Mull

Eric Mull has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170252432
    Abstract: The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 1, 2017
    Publication date: September 7, 2017
    Inventors: Martin Patrick Allen, Eric P. Gillis, David R. Langley, Michael Matthew Miller, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Katharine A. Grant-Young, Nicholas A. Meanwell, Paul Michael
  • Patent number: 9732119
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: August 15, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20170107202
    Abstract: The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 11, 2016
    Publication date: April 20, 2017
    Inventors: KAP-SUN YEUNG, Timothy P. Connolly, David B. Frennesson, Katharine A. Grant-Young, Piyasena Hewawasam, David R. Langley, Zhaoxing Meng, Eric Mull, Kyle E. Parcella, Mark George Saulnier, Li-Qiang Sun, Alan Xiangdong Wang, Ningning Xu, Juliang Zhu, Paul Michael Scola
  • Patent number: 9624245
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: April 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Tao Wang, Zhongxing Zhang, Zhiwei Yin, Li-Qiang Sun, Eric Mull, Qian Zhao, Paul Michael Scola
  • Patent number: 9598433
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 21, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola
  • Patent number: 9527885
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: December 27, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
  • Publication number: 20160340391
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: July 7, 2016
    Publication date: November 24, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Li-Qiang Sun, Kap-Sun Yeung, Patrick C. Reid, Paul Michael Scola
  • Patent number: 9499550
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: November 22, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
  • Publication number: 20160272680
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: March 14, 2016
    Publication date: September 22, 2016
    Inventors: Kenneth M. Boy, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20160222060
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: February 1, 2016
    Publication date: August 4, 2016
    Inventors: Michael Matthew Miller, Martin Patrick Allen, Ling Li, Claudio Mapelli, Maude A. Poirier, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20160176928
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 23, 2016
    Inventors: Li-Qiang Sun, Qian Zhao, Eric P. Gillis, Michael Matthew Miller, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • Publication number: 20160175386
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: December 14, 2015
    Publication date: June 23, 2016
    Inventors: Claudio Mapelli, Eric P. Gillis, Li-Qiang Sun, Qian Zhao, Martin Patrick Allen, Eric Mull, Paul Michael Scola
  • Publication number: 20160158349
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: January 28, 2016
    Publication date: June 9, 2016
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Publication number: 20160137696
    Abstract: The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: November 11, 2015
    Publication date: May 19, 2016
    Inventors: Kevin W. Gillman, Jason Goodrich, Kenneth M. Boy, Yunhui Zhang, Claudio Mapelli, Michael A. Poss, Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Publication number: 20160102122
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Application
    Filed: October 5, 2015
    Publication date: April 14, 2016
    Inventors: Li-Qiang Sun, Qian Zhao, Eric Mull, Eric P. Gillis, Paul Michael Scola
  • Patent number: 9308236
    Abstract: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 12, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Matthew Miller, Claudio Mapelli, Martin Patrick Allen, Michael S. Bowsher, Kenneth M. Boy, Eric P. Gillis, David R. Langley, Eric Mull, Maude A. Poirier, Nishith Sanghvi, Li-Qiang Sun, Daniel J. Tenney, Kap-Sun Yeung, Juliang Zhu, Patrick C. Reid, Paul Michael Scola
  • Publication number: 20150368267
    Abstract: Compounds of Formula I, including pharmaceutically acceptable salts thereof, are set forth, in addition to compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.
    Type: Application
    Filed: February 4, 2014
    Publication date: December 24, 2015
    Inventors: Tao WANG, Zhongxing ZHANG, Zhiwei YIN, Li-Qiang SUN, Eric MULL, Qian ZHAO, Paul Michael SCOLA
  • Publication number: 20150284409
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 8, 2015
    Inventors: Li-Qiang Sun, Eric P. Gillis, Eric Mull, Michael S. Bowsher, Qian Zhao, Paul Michael Scola
  • Publication number: 20150284391
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: October 19, 2012
    Publication date: October 8, 2015
    Inventors: Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola
  • Publication number: 20150125422
    Abstract: Hepatitis C virus inhibitors having the general formula (I) are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
    Type: Application
    Filed: January 8, 2015
    Publication date: May 7, 2015
    Inventors: Sheldon Hiebert, Ramkumar Rajamani, Li-Qiang Sun, Eric Mull, Eric P. Gillis, Michael S. Bowsher, Qian Zhao, Nicholas A. Meanwell, Kishore V. Renduchintala, Kandhasamy Sarkunam, Pulicharla Nagalakshmi, P.V.K. Suresh Babu, Paul Michael Scola